Synta Pharmaceuticals Announces Presentation of Ganetespib Results at the 2013 European Cancer Congress
Published: Sep 30, 2013
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced presentation of results from the GALAXY-1 trial, a global, randomized, multi-center Phase 2b/3 study designed to identify the patients with advanced non-small cell lung adenocarcinoma most likely to benefit from second-line treatment with the Company’s lead drug candidate, the Hsp90 inhibitor ganetespib.
Help employers find you! Check out all the jobs and post your resume.